AstraZeneca has drawn up plans to break out its China business and list it separately in Hong Kong as a way to shelter the company against mounting geopolitical tensions. The Anglo-Swedish drugmaker began discussing the idea with bankers several months ago and is among a growing number of multinational companies now considering that option, according to three people familiar with the talks.
阿斯特捷利康(AstraZeneca)已擬定計劃，分拆其中國業務並在香港單獨上市，以規避日益加劇的地緣政治緊張局勢影響。
您已閱讀9%（451字），剩餘91%（4412字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。